BSI-060T

N/A

Report date: 2026/05/09 20:00:18

Base Information

Drug NameBSI-060T
Drug Alias NameBSI-060TPYX-106
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionSialic acid-binding Ig-like lectin 15 inhibitors
TargetsSialic acid-binding Ig-like lectin 15
Therapy Area/IndicationsSolid tumoursNeoplasm Metastasis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesSpain +[4] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBiosion Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesPyxis Oncology IncBiosion Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursNeoplasm Metastasis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A